Insmed's Lung Drug Hopes Rise After NASDAQ Exit

Insmed Incorporated experienced a removal from the NASDAQ-100 Index on June 19, 2026. This event, however, has not diminished investor focus on the company's promising experimental lung drug, TPIP. The upcoming clinical data for TPIP is now highlighted as a pivotal moment for Insmed's rare respiratory disease portfolio and its broader financial future.

Analysts anticipate that the data readout for TPIP could significantly reshape Insmed's current clinical and earnings trajectory. While the NASDAQ-100 delisting is viewed as a technical adjustment rather than a fundamental shift, the success of TPIP's trials and the U.S. launch timing for brensocatib remain critical near-term catalysts, alongside execution risks.

The ENCORE Phase 3b readout for ARIKAYCE in March 2026 has bolstered expectations for Insmed's existing franchise. With improved outcomes and plans for a broader MAC lung disease label in the latter half of 2026, the company's current offerings show potential for growth even as attention shifts to TPIP. This suggests Insmed's narrative is supported by both established and emerging assets.